The US Food and Drug Administration has approved Kynamro, a gene silencing drug from Isis Pharmaceuticals, to treat homozygous familial hypercholesterolemia, The New York Times reports. The drug will be marketed by Sanofi's Genzyme division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Natural Knockouts

This Week in Nature

More to Lose

Human Knockouts

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.